Communications Medicine

Communications Medicine is a selective open access medical journal from Nature Portfolio, published by Springer Nature since its first articles appeared on 30 June 2021, covering clinical, translational and public health research for specialist readerships and holding a 2025 Journal Impact Factor of 7.4 with a rank of 31st among 191 journals in research and experimental medicine《通讯医学》（Communications Medicine）是（Nature Portfolio）旗下精选型开放获取医学期刊，由（Springer Nature）出版，2021 年 6 月 30 日发表首批文章，覆盖面向专业读者的临床、转化与公共卫生研究，2025 年影响因子 7.4，在 191 种研究与实验医学期刊中列第 31 位。

Scope

• The journal spans all medical specialties, from oncology and neurology to infectious disease and mental health, judged by interest to a specialist audience rather than by novelty alone该刊覆盖全部医学专科，从肿瘤学、神经病学到传染病与精神卫生，取舍标准是能否引起专科读者兴趣而不只是新颖程度。
• Translational work that moves biomedical discovery toward clinical practice or population health is a defining strand, including early human studies and proof of concept work把生物医学发现推向临床实践或人群健康的转化研究是其标志性方向，涵盖早期人体研究与概念验证工作。
• Public health and epidemiology are treated as core rather than peripheral, with explicit attention to health inequalities, access to care and inclusive representation in research公共卫生与流行病学被视为核心而非边缘内容，并明确关注健康不平等、就医可及性与研究中的包容性代表性。
• Work at the intersection with computational science, physics and engineering is welcomed where it is of interest to a medical readership, including digital pathology and clinical artificial intelligence与计算科学、物理学和工程学的交叉研究只要对医学读者有意义即受欢迎，包括数字病理与临床人工智能。
• Prevention, diagnosis and treatment of disease form the three clinical pillars, with diagnostic accuracy, screening and therapeutic evaluation all inside the remit疾病的预防、诊断与治疗构成三大临床支柱，诊断准确性、筛查与治疗效果评价均属收稿范围。
• Article formats include full and shorter research Articles, Matters Arising, and commissioned Reviews, Perspectives, Comments and Viewpoints, with a Plain Language Summary required for research papers文章类型包括全文与短篇研究论文、商榷文章，以及约稿综述、视角、评论与观点，研究论文须附通俗语言摘要。
• Data, code and materials must be described in enough detail to be accessed, and authors may opt in to transparent peer review so that referee reports appear beside the paper数据、代码与材料须描述到可被获取的程度，作者还可选择透明评审，使审稿意见与论文同时刊出。

History

• The journal was launched in June 2021 as one of the Communications titles that sit alongside Nature Communications, extending the family into medicine and public health该刊于 2021 年 6 月创办，是（Nature Communications）周边通讯系列的一员，把该系列延伸至医学与公共卫生领域。
• Within a year it had received more than 500 submissions from authors in 47 countries and published over 100 articles, and its editorial board grew from 9 members at launch to 27创刊一年内即收到来自 47 个国家作者的 500 余篇投稿，发表文章逾 100 篇，编委会由创刊时的 9 人增至 27 人。
• By its fourth anniversary in 2025 it had published more than 900 papers from 55 countries, with an editorial team of seven in-house editors and 66 board members到 2025 年四周年时，该刊已发表来自 55 个国家的 900 余篇论文，编辑团队含 7 位专职编辑与 66 位编委。
• Publication is continuous, with no print edition and no fixed issue boundaries, and articles appear under a Creative Commons Attribution licence该刊连续出版，无纸本版也无固定期次界限，文章以知识共享署名许可发布。
• It is indexed in the Emerging Sources Citation Index, PubMed Central, Scopus, DOAJ, CNKI, Dimensions and Google Scholar, and the journal notes that full indexing follows gradually for new titles该刊被（Emerging Sources Citation Index）、（PubMed Central）、（Scopus）、（DOAJ）、（CNKI）、（Dimensions）与（Google Scholar）收录，期刊并说明新刊的完整收录需逐步完成。
• Its impact factor moved from 6.3 in 2024 to 7.4 in 2025, and more than half of the papers it published in 2025 were linked to one or more of the United Nations Sustainable Development Goals该刊影响因子由 2024 年的 6.3 升至 2025 年的 7.4，2025 年发表的文章中有半数以上与联合国可持续发展目标中的一项或多项相关。

Editors

• The chief editor is Xin Sun, a biochemist by training who worked on NF-kappaB signalling and the DNA damage response before moving from the Journal of Experimental Medicine, where she became a deputy editor, to lead Communications Medicine in April 2025现任主编为（Xin Sun），她受过生物化学训练，研究过核因子 κB 信号与 DNA 损伤应答，此前在（Journal of Experimental Medicine）升任副编辑，2025 年 4 月出任本刊主编。
• Katharine Barnes, a cancer pharmacologist and former editor of Trends in Pharmacological Sciences and Nature Protocols, serves as a senior editor on secondment from the London office（Katharine Barnes）为借调至该刊的资深编辑，她是肿瘤药理学家，曾任（Trends in Pharmacological Sciences）与（Nature Protocols）编辑，驻伦敦办公室。
• Three further senior editors and a group of associate editors, based in New York, London, Philadelphia and Beijing, handle manuscripts across the journal's clinical and public health range另有三位资深编辑与一组副编辑分驻纽约、伦敦、费城与北京，处理该刊临床与公共卫生各领域的稿件。
• The editorial model pairs an in-house team of professionally trained scientific editors with academic editors who take responsibility for individual manuscripts while staying in close contact with the office其编辑模式把受过专业训练的专职科学编辑团队与学术编辑相结合，后者负责具体稿件并与编辑部保持密切联系。
• The board has expanded to 66 active researchers and clinicians covering a broad range of specialties and countries, and the journal runs an early career researcher co-review pilot so that less experienced referees gain supervised reviewing practice编委会已扩至 66 位活跃研究者与临床医生，覆盖广泛的专科与国别，期刊并开展青年研究者共同审稿试点，让经验较少的评审人在指导下积累审稿经验。
• Registered Reports, in which acceptance depends on the study design rather than the results, have been piloted in partnership with Cancer Research UK alongside other journals该刊与（Cancer Research UK）及其他期刊合作，试点注册报告形式，其录用取决于研究设计而非结果。